Therefore, oncoproteins such as ABL1, which have been found to be mutated only in a subset of leukemia patients, could be more directly actionable with ABL1-targeting tyrosine kinase inhibitors, such as imatinib, nilotinib, dasatinib, bosutinib and ponatinib, all of which are approved for ABL1-driven diseases. The gene discussed is ABL1; the disease is leukemia.